New drug targets Hard-to-Treat blood cancers in early trial
NCT ID NCT04830137
First seen Apr 25, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This early-stage study tests a new drug called NX-2127 in adults with certain blood cancers (like CLL or lymphoma) that have returned or not improved after other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 248 people will take part in this first human trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA (FL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor University Medical Center
COMPLETEDDallas, Texas, 75246, United States
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
-
Huntsman Cancer Institute, University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
COMPLETEDNew York, New York, 10065, United States
-
Mount Sinai Comprehensive Cancer Center
COMPLETEDMiami Beach, Florida, 33140, United States
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20814, United States
-
OSU Wexner Medical Center
COMPLETEDColumbus, Ohio, 43210, United States
-
Sarah Cannon Research Institute at Colorado Blood Cancer Institute
RECRUITINGDenver, Colorado, 80218, United States
-
Sarah Cannon Research Institute at Florida Cancer Specialists
COMPLETEDSarasota, Florida, 34203, United States
-
Swedish Cancer Institute
COMPLETEDSeattle, Washington, 98104, United States
-
Tennessee Oncology
RECRUITINGNashville, Tennessee, 37203, United States
-
The University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
-
University of California Irvine
COMPLETEDOrange, California, 92868, United States
-
University of California San Francisco Medical Center
COMPLETEDSan Francisco, California, 94143, United States
-
University of Cincinnati Medical Center
COMPLETEDCincinnati, Ohio, 45267, United States
Conditions
Explore the condition pages connected to this study.